Since the Hsp90 inhibitor by itself could inhibit both driver (from rearranged ALK) and resistance signals (from activated receptors; MET and EGFR), it may be an ideal agent for overcoming ligand-triggered alectinib resistance in ALK-rearranged NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.